Search

Elekta AB

Fechado

60.3 -0.82

Visão Geral

Variação de preço das ações

24h

Atual

Mín

59.5

Máximo

60.7

Indicadores-chave

By Trading Economics

Rendimento

94M

230M

Vendas

424M

4.1B

P/E

Médio do Setor

79.737

89.037

EPS

0.64

Rendimento de Dividendos

3.92

Margem de lucro

5.651

Funcionários

4,484

EBITDA

20M

529M

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.92%

2.18%

Próximos Ganhos

5 de mar. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

6.6B

23B

Abertura anterior

61.12

Fecho anterior

60.3

Elekta AB Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de jan. de 2026, 23:07 UTC

Ganhos

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 de jan. de 2026, 21:27 UTC

Ganhos

Texas Instruments 4Q Sales Rise, Profit Falls

27 de jan. de 2026, 23:55 UTC

Conversa de Mercado

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 de jan. de 2026, 23:47 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de jan. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 de jan. de 2026, 23:39 UTC

Conversa de Mercado

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 de jan. de 2026, 23:20 UTC

Ganhos

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 de jan. de 2026, 23:20 UTC

Ganhos

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 de jan. de 2026, 23:19 UTC

Ganhos

SK Innovation Posts Net Loss for Second Consecutive Year

27 de jan. de 2026, 23:19 UTC

Ganhos

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 de jan. de 2026, 23:18 UTC

Ganhos

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 de jan. de 2026, 23:18 UTC

Ganhos

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 de jan. de 2026, 23:11 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de jan. de 2026, 23:11 UTC

Conversa de Mercado

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 de jan. de 2026, 23:07 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 de jan. de 2026, 22:17 UTC

Conversa de Mercado

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 de jan. de 2026, 22:06 UTC

Ganhos

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 de jan. de 2026, 21:51 UTC

Ganhos

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 de jan. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

27 de jan. de 2026, 21:43 UTC

Ganhos

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 de jan. de 2026, 21:41 UTC

Ganhos

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 de jan. de 2026, 21:38 UTC

Ganhos

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 de jan. de 2026, 21:32 UTC

Ganhos

Ampol: Modest Profit From F&I International in 2025

27 de jan. de 2026, 21:32 UTC

Ganhos

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 de jan. de 2026, 21:31 UTC

Ganhos

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 de jan. de 2026, 21:31 UTC

Ganhos

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 de jan. de 2026, 21:30 UTC

Ganhos

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 de jan. de 2026, 21:29 UTC

Ganhos

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 de jan. de 2026, 21:29 UTC

Ganhos

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 de jan. de 2026, 21:28 UTC

Ganhos

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Elekta AB Previsão

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Elekta AB

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
help-icon Live chat